Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Ended earlyNCT05849246
What this trial is testing

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Who this might be right for
Non-squamous Non-small-cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. 4
Testing effectiveness (Phase 2)Ended earlyNCT05245071
What this trial is testing

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Sanofi 22
Large-scale testing (Phase 3)Not Yet RecruitingNCT07829549
What this trial is testing

Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Who this might be right for
Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
RemeGen Co., Ltd. 540
Large-scale testing (Phase 3)Looking for participantsNCT06561386
What this trial is testing

Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Who this might be right for
Non-small Cell Lung Cancer
Bristol-Myers Squibb 1,000
Large-scale testing (Phase 3)Not Yet RecruitingNCT06961188
What this trial is testing

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Who this might be right for
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene NegativityUntreated With Systemic Therapy
Changchun GeneScience Pharmaceutical Co., Ltd. 174
Testing effectiveness (Phase 2)Ended earlyNCT04524689
What this trial is testing

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Who this might be right for
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Sanofi 57
Testing effectiveness (Phase 2)Ended earlyNCT04394624
What this trial is testing

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Sanofi 31